Welcome to our dedicated page for Biorestorative Therapies SEC filings (Ticker: BRTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BioRestorative Therapies, Inc. (NASDAQ: BRTX) SEC filings page on Stock Titan provides access to the company’s regulatory documents as filed with the U.S. Securities and Exchange Commission. BioRestorative is a biotechnology issuer that develops adult stem cell-based therapies and products, and its filings offer detailed insight into the disc/spine, metabolic, and BioCosmeceutical programs that it highlights in its public communications.
Through this page, users can review annual reports on Form 10-K and quarterly reports on Form 10-Q, which BioRestorative identifies in its S-1 registration statement as being incorporated by reference. These reports discuss risk factors, management’s discussion and analysis, and financial statements related to its clinical-stage BRTX-100 program for degenerative disc disease, the ThermoStem® metabolic platform targeting obesity and metabolic disorders, and its commercial BioCosmeceutical activities.
Investors can also examine current reports on Form 8-K that BioRestorative files to describe material events. Recent examples include disclosures about a registered direct offering of common stock with concurrent private placement of unregistered warrants, the use of proceeds for BRTX-100 clinical trials and ThermoStem® preclinical research, stockholder meeting results, and the release of quarterly financial results and corporate presentations.
In addition, this page surfaces registration statements such as Form S-1 and Form S-3, where BioRestorative outlines the terms of offerings, the status of its common stock on the NASDAQ Capital Market, and the documents incorporated by reference. Users interested in executive compensation, governance, and voting matters can consult the company’s definitive proxy statement on Schedule 14A.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand topics such as capital raises, clinical program disclosures, and stock incentive plan changes. Real-time updates from EDGAR ensure that new BRTX filings, including Forms 3, 4, and 5 related to insider transactions when available, are added promptly for ongoing analysis.
BioRestorative Therapies, Inc. is registering up to 508,592 shares of common stock for resale by existing securityholders. These shares are issuable upon exercise of outstanding warrants and may be sold over time on the Nasdaq Capital Market or in private transactions at market, fixed, or negotiated prices.
The company reports 8,876,242 shares of common stock outstanding as of November 17, 2025. BioRestorative will not receive any proceeds from the resale of shares by the selling securityholders, but would receive up to $1,398,628 in gross proceeds if all related warrants are exercised at the $2.75 per share exercise price. The prospectus highlights that an investment in the stock involves a high degree of risk and that the most recent audited financial statements include an auditor’s explanatory paragraph about the company’s ability to continue as a going concern.
BioRestorative Therapies, Inc. is registering 3,000,000 additional shares of its common stock for issuance under its 2021 Stock Incentive Plan. These shares may be used for stock options and other awards granted to eligible participants under the plan, and the registration also extends to any extra shares that might result from stock dividends, splits or similar corporate actions. The company notes that this filing supplements four earlier Form S-8 registrations that together covered prior share amounts under the same plan. Legal matters for the newly registered shares are being handled by Certilman Balin Adler & Hyman, LLP, which is also a stockholder of the company, and the filing restates the company’s indemnification and liability protections for directors and officers under Nevada law.
BioRestorative Therapies, Inc. is registering up to 508,592 shares of common stock for resale by existing selling securityholders, with the shares issuable upon exercise of certain warrants. The warrants have an exercise price of $2.75 per share, and the company would receive up to $1,398,628 in gross proceeds only if they are fully exercised, which it currently plans to use for general corporate purposes and working capital, including its clinical trial and other initiatives. As of November 17, 2025, 8,876,242 shares of common stock were outstanding, a baseline figure for the company’s equity. BioRestorative develops cell-based therapies for spine disease (BRTX-100), metabolic disorders (ThermoStem) and operates a commercial biocosmeceutical platform. The shares will be sold from time to time by the selling securityholders, and investing in this stock is described as involving a high degree of risk, with the company’s audited financials including a going concern explanatory paragraph.
BioRestorative Therapies, Inc. (BRTX) filed its Q3 10‑Q, reporting a continuing operating loss as it advances clinical and product initiatives. Q3 revenue was $11,800 (mainly royalties) versus $233,600 a year ago, reflecting timing of cosmetic product orders. Research and development rose to $2,594,750 in the quarter as Phase 2 trial activity increased. Q3 net loss was $3,038,277; for the nine months, revenue was $340,100 and net loss was $11,034,339.
Liquidity tightened: cash was $602,444 and marketable securities were $3,887,383 at September 30, 2025, with working capital of $1,271,781. Management disclosed “substantial doubt” about the company’s ability to continue as a going concern. To raise capital, BRTX sold 965,424 shares under its ATM for $2,011,250 gross in the nine‑month period, and on October 8, 2025 closed a registered offering of 678,125 shares for approximately $1.1 million alongside 508,592 new warrants at a $2.75 exercise price.
Material weaknesses in internal control over financial reporting remained as of September 30, 2025. Shares outstanding were 8,876,242 as of November 11, 2025.
BioRestorative Therapies, Inc. filed a current report to note that it issued a press release on November 12, 2025 announcing its financial results for the third quarter ended September 30, 2025. The release also includes a broader business update and information about a conference call to discuss the quarter.
The press release is furnished as Exhibit 99.1 and, as the company emphasizes, is provided under the rules for furnished, not filed, information. That means it is not automatically subject to certain Exchange Act liabilities and will only be incorporated into other SEC filings if specifically referenced.
BioRestorative Therapies, Inc. filed a Form D reporting a completed private offering under Rule 506(b) that raised $1,398,628. The filing shows 16 investors participated and the Total Remaining to be Sold is $0, indicating the stated offering amount was sold in full. The issuer reports No Revenues and No Aggregate Net Asset Value on the form, and states the offering was not intended to run longer than one year. Sales commissions and finders' fees are reported as $0 for this notice, and the company identified Cova Capital Partners LLC as a solicitor with an address in New York. The form is signed by Robert Kristal, Chief Financial Officer, on 2025-10-09.
BioRestorative Therapies, Inc. entered into subscription agreements for a registered direct offering of 678,125 common shares at $1.60 per share, for gross proceeds of $1.085 million before fees. In a concurrent private placement, investors receive unregistered warrants to purchase up to 508,592 additional shares at an exercise price of $2.75.
The company plans to use net proceeds to fund clinical trials for its BRTX-100 cell therapy, pre-clinical work on its ThermoStem metabolic program, development of a commercial biocosmeceuticals platform, and for general corporate purposes and working capital. The unregistered warrants are exercisable six months after issuance for five years, include a 4.99% beneficial ownership cap, allow cashless exercise if no resale registration is effective, and may be redeemed by the company for $1.00 per warrant if the stock trades above $5.00 for ten consecutive trading days. A placement agent will receive cash fees, expense reimbursement and a warrant based on a percentage of shares sold.
BioRestorative Therapies, Inc. is offering common stock and conducting a related warrant private placement while disclosing key financing and program details. The prospectus shows a public offering price structure where the company would receive $1.504 per share before expenses and the placement agent fee is $0.096 per share, representing an aggregate placement fee of $65,100 and proceeds before expenses of $1,019,900. The company reports a net tangible book value per share of $0.53 as of June 30, 2025.
The filing also summarizes clinical and R&D programs: an FDA authorization to commence a Phase 2 trial of BRTX-100 for degenerative disc disease, active trial setup and enrollment activities, and an issued U.S. patent (March 2022) with exclusive license rights for BRTX-100. The ThermoStem metabolic program targets obesity using brown adipose–derived cells and has issued patents in the U.S. and elsewhere. The prospectus lists financing, regulatory, clinical, manufacturing, IP, reimbursement and dilution risks that could affect operations and the market price of the company’s securities.
BioRestorative Therapies is amending its at-the-market common stock offering to an aggregate offering price of up to $1,017,040 under its agreement with Rodman & Renshaw LLC. This prospectus supplement updates the prior prospectus supplement and forms part of the company’s existing Form S-3 shelf registration.
The company states that its public float is $12,339,869, calculated using 6,706,451 shares of common stock held by non-affiliates at $1.84 per share as of August 29, 2025, and that it has sold $2,011,249 of common stock under the registration statement during the last 12 calendar months pursuant to General Instruction I.B.6. The shares trade on the Nasdaq Capital Market under the symbol BRTX, with a last reported sales price of $1.50 per share on October 3, 2025.
BioRestorative Therapies, Inc. reported the results of its Annual Meeting of Stockholders held on September 18, 2025. Stockholders elected Class II directors Francisco Silva and David Rosa, each receiving over 1.47 million votes in favor, with more than 3.32 million broker non-votes recorded for each nominee.
Stockholders also approved an amendment to the 2021 Stock Incentive Plan to increase the number of shares of common stock authorized under the plan from 6,850,000 to 9,850,000. In addition, they ratified the selection of CBIZ CPAs P.C. as independent registered public accounting firm for the fiscal year ending December 31, 2025, and approved, on a non-binding advisory basis, the compensation of the Company’s executive officers.